Johnson & Johnson (JNJ) Holdings Increased by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 1.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,953 shares of the company’s stock after acquiring an additional 479 shares during the period. Johnson & Johnson makes up 0.4% of Checchi Capital Advisers LLC’s investment portfolio, making the stock its 18th largest position. Checchi Capital Advisers LLC’s holdings in Johnson & Johnson were worth $3,513,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock valued at $136,289,000 after buying an additional 38,285 shares in the last quarter. Concentric Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Concentric Wealth Management LLC now owns 26,611 shares of the company’s stock valued at $3,229,000 after buying an additional 813 shares in the last quarter. Narwhal Capital Management raised its holdings in shares of Johnson & Johnson by 2.5% during the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock valued at $4,965,000 after buying an additional 1,010 shares in the last quarter. Cardinal Capital Management raised its holdings in shares of Johnson & Johnson by 10.6% during the 2nd quarter. Cardinal Capital Management now owns 101,715 shares of the company’s stock valued at $12,342,000 after buying an additional 9,767 shares in the last quarter. Finally, Professional Advisory Services Inc. raised its holdings in shares of Johnson & Johnson by 18.7% during the 2nd quarter. Professional Advisory Services Inc. now owns 138,922 shares of the company’s stock valued at $16,857,000 after buying an additional 21,917 shares in the last quarter. 66.06% of the stock is currently owned by hedge funds and other institutional investors.

JNJ has been the topic of a number of research reports. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a report on Friday, September 14th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Raymond James raised their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Finally, Citigroup raised their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $143.47.

In other Johnson & Johnson news, CEO Alex Gorsky sold 264,465 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $145.96, for a total value of $38,601,311.40. Following the transaction, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. Insiders sold a total of 351,748 shares of company stock worth $51,092,647 over the last ninety days. Insiders own 0.22% of the company’s stock.

Shares of Johnson & Johnson stock opened at $146.90 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The company has a market capitalization of $394.12 billion, a price-to-earnings ratio of 20.12, a P/E/G ratio of 2.30 and a beta of 0.58. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.75.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.90 EPS. As a group, equities analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be paid a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a yield of 2.45%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2018/12/03/johnson-johnson-jnj-holdings-increased-by-checchi-capital-advisers-llc.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Coverage Ratio

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit